Infection control important for high-risk patients

NEW YORK (Reuters Health) - The best way to protect high-risk cancer patients from life-threatening infection is to combine preventive antibiotics and antifungal treatment with isolation and other methods, such as the use of gloves and face masks, according to a new review of 40 studies.

Chemotherapy destroys cancer patients’ blood cells, including white blood cells that are responsible for immune protection, leaving the patients vulnerable to infection. Recipients of bone marrow transplants are also at very high risk. Before they can receive the transplant, patients must first have all of their own immune cells destroyed.

Infections are the leading cause of preventable death among cancer patients, Dr. Mical Paul of Rabin Medical Center in Petah-Tikva, Israel, and his colleagues note in their report in Lancet Infectious Diseases. However, there is no consensus on the best way to protect these patients, they add, which is particularly important today given the increase in drug resistance among disease-causing organisms.

To investigate, Paul and his team reviewed published studies comparing various infection control measures among high-risk patients undergoing chemotherapy or bone marrow transplants. Among the 40 studies they reviewed, which were published between 1971 and 2008, there were 26 that used isolation to protect patients — for example, controlling air flow to and from the patient’s bed and putting barriers between the patient and the outside environment.

While isolation methods alone did not seem to significantly reduce mortality and infections among the cancer patients, isolation methods combined with prophylactic antibiotics reduced the 30-day mortality from any cause by 40 percent, the researchers found.

In the studies with the longest follow-up, the combined methods reduced 3-year mortality risk by 14 percent. Isolation plus antibiotics also reduced bacterial infections of the blood, infections with Gram-negative and Gram-positive bacteria and Candida (yeast) infections. The intervention did not have a significant effect on the risk of mold infections.

Eleven studies that compared inpatient with outpatient treatment after bone marrow transplant found that outpatients were 18 percent less likely to die. The researchers note however that the patients treated on an outpatient basis may have been healthier than those treated in the hospital.

The older studies included in the review, done before the development of stronger antibiotic and antifungal drugs, may not be relevant to current practice, the researchers say. But infections are still a key factor in how patients fare after treatment, they add, and the same types of organisms still infect patients.

“The current absolute gain in survival is probably higher than that observed in older studies, in which a larger proportion of patients died from their underlying disease,” the researchers write.

They suggest that clinical trials that randomly assign patients to a treatment group be performed to see if outpatient treatment of stem cell transplant patients is indeed as safe and effective as impatient care.

SOURCE: Lancet Infectious Diseases, February 2009.


Related Posts:

BERLIN (Reuters) - A bone marrow transplant using stem cells from a donor with natural genetic resistance to the AIDS virus has left an HIV patient free of infection for nearly two years, German researchers. The patient, an American living in Berlin, was infected with the human immunodeficiency virus that causes AIDS and also had leukemia.

Full Post: Bone marrow transplant suppresses AIDS in patient

By Julie Steenhuysen CHICAGO (Reuters) - Leukemia cells use powerful chemical signals to lure healthy blood-forming stem cells into their cancerous lairs, where they lose their power to make healthy blood cells, U.S. researchers said on Thursday. But by jamming these signals in mice, the team was able to protect the stem cells, called hematopoietic progenitor cells. If

Full Post: Fatal attraction: How leukemia seduces blood cells

By Michael Kahn LONDON (Reuters) - A novel drug combination using Genzyme Corp’s Mozobil shows it may be possible to spur bone marrow into releasing extra adult stem cells into the bloodstream to repair the heart and broken bones, researchers said on Thursday. The study of mice raises hope that researchers could use the same technique to

Full Post: New drug combo may boost stem cell production

ZURICH (Reuters) - Novartis AG’s cancer drug Tasigna was effective and helped achieve rapid responses as an initial therapy in newly diagnosed patients with a life threatening form of leukemia, the company said. Data from two mid-stage clinical trials presented at an American Society of Hematology meeting showed there was rapid elimination of cancer cells in

Full Post: Novartis leukemia drugs show promise

By Michael Kahn LONDON (Reuters) - Doctors may one day be able to use stem cells taken from umbilical cord blood to build new heart valves for children born with heart defects, German scientists said on Monday. These valves could grow as a child develops, doing away with any need for repeated operations to replace outgrown artificial

Full Post: Umbilical cord blood may help build heart valves

Site Navigation

Most Read